InvestSMART

Cynata Therapeutics Limited (ASX: CYP) - Announcements

- Current share price for CYP : $0.011

ASX company news and announcements for Cynata Therapeutics Limited (CYP) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Cynata Therapeutics Limited (CYP) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Cynata Therapeutics Limited (CYP), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Cynata Therapeutics Limited (CYP)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$3 June 2026 Quarterly Activity Report & Appendix 4C 30 Jul 2026 11:02AM $0.012 $0.011 fallen by 8.33%
$3 Notification of cessation of securities - CYP 10 Jul 2026 8:38AM $0.014 $0.011 fallen by 21.43%
$3 Final Director's Interest Notice 6 Jul 2026 8:37AM $0.013 $0.011 fallen by 15.38%
$3 Board, Management Changes, Expenditure Reductions, RDTI Loan 6 Jul 2026 8:35AM $0.013 $0.011 fallen by 15.38%
$3 Ceasing to be a substantial holder 2 Jul 2026 6:31PM $0.014 $0.011 fallen by 21.43%
$3 Change in substantial holding 2 Jul 2026 8:15AM $0.014 $0.011 fallen by 21.43%
$3 Becoming a substantial holder 30 Jun 2026 8:57AM $0.012 $0.011 fallen by 8.33%
$3 Ceasing to be a substantial holder 23 Jun 2026 3:47PM $0.016 $0.011 fallen by 31.25%
$3 Investor Webinar 22 Jun 2026 8:19AM $0.018 $0.011 fallen by 38.89%
$3 Reinstatement to Official Quotation 19 Jun 2026 9:22AM $0.260 $0.011 fallen by 95.77%
$3 CYP-004 Osteoarthritis Trial Results 19 Jun 2026 9:22AM $0.260 $0.011 fallen by 95.77%
$3 CYP-001 GvHD Trial Primary Evaluation Results 17 Jun 2026 12:05PM $0.260 $0.011 fallen by 95.77%
$3 Suspension from Quotation 16 Jun 2026 8:53AM $0.260 $0.011 fallen by 95.77%
$3 Trading Halt 12 Jun 2026 9:46AM $0.260 $0.011 fallen by 95.77%
$3 EU Positive Opinion on CYP-001 Paediatric Investigation Plan 3 Jun 2026 8:48AM $0.275 $0.011 fallen by 96%
$3 WHO Selects Proposed INN for Cymerus MSCs 29 May 2026 8:56AM $0.255 $0.011 fallen by 95.69%
$3 Expected Timing of Clinical Trial Results 27 May 2026 8:54AM $0.260 $0.011 fallen by 95.77%
$3 Cleansing Notice 8 May 2026 9:01AM $0.315 $0.011 fallen by 96.51%
$3 Application for quotation of securities - CYP 8 May 2026 8:57AM $0.315 $0.011 fallen by 96.51%
$3 Proposed issue of securities - CYP 4 May 2026 9:05AM $0.323 $0.011 fallen by 96.59%
$3 Cynata Secures Commitments for $1.5m Placement 4 May 2026 9:05AM $0.323 $0.011 fallen by 96.59%
$3 March 2026 Quarterly Activity Report & Appendix 4C 30 Apr 2026 10:00AM $0.323 $0.011 fallen by 96.59%
$3 Trading Halt 30 Apr 2026 9:03AM $0.323 $0.011 fallen by 96.59%
$3 Notification of cessation of securities - CYP 7 Apr 2026 8:31AM $0.295 $0.011 fallen by 96.27%
$3 Last Visit in GvHD Trial Completed 30 Mar 2026 8:58AM $0.300 $0.011 fallen by 96.33%

1 - 25 of 699 results

Page 1 of 28

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.